Trial Profile
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral CGM097, a p53/HDM2-interaction Inhibitor, in Adult Patients With Selected Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs CGM 097 (Primary)
- Indications Colorectal cancer; Malignant melanoma; Osteosarcoma; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Novartis; Novartis Pharmaceuticals
- 17 Jun 2021 Results assessing the safety, MTD, PK/PD and preliminary antitumor activity of CGM097 in advanced solid tumour patients published in the British Journal of Cancer
- 29 Jul 2020 Status changed from active, no longer recruiting to completed.
- 12 Feb 2020 Planned End Date changed from 19 Dec 2019 to 1 Jul 2020.